TY - JOUR
T1 - Comparative phase III tazobactam/piperacillin and ceftazidime study in the treatment of community-acquired pneumonia
AU - Watanabe, Akira
AU - Aoki, Nobuki
AU - Chida, Kingo
AU - Niki, Yoshihito
AU - Saito, Atsushi
AU - Kohno, Shigeru
AU - Kadota, Jun Ichi
AU - Shiba, Kohya
N1 - Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2010/3
Y1 - 2010/3
N2 - A randomized, unblinded, multicenter study was conducted to compare efficacy and safety of tazobactam/piperacillin(TAZ/PIPC), a β-lactamase inhibitor combined with penicillin antibiotic, to those of ceftazidime (CAZ) in patients with community-acquired pneumonia. Subjects were assigned to TAZ/PIPC (4.5 g three times daily) or CAZ (2 g twice daily) groups for a maximum administration of 14 days. Results were obtained as follows: 1. Clinical effect: Response at completion or discontinuation of treatment was 91.3% (95/104 patients) in the TAZ/PIPC group and 89.9% (98/109 patients) in the CAZ group. These results verified the noninferiority of TAZ/PIPC to CAZ in clinical effect. Response evaluated seven days after completion of treatment was 90.8% (89/98 patients) in the TAZ/PIPC group and 84.8% (89/105 patients) in the CAZ group. 2. Bacteriological effect: Bacteria disappearance in patients at completion or discontinuation of treatment was 100% (45/45 patients) in the TAZ/PIPC group and 93.8% (45/48 patients) in the CAZ group. Bacteria disappearance in pathogens was 100% (49/49 strains) in the TAZ/PIPC group and 94.0% (47/50 strains) in the CAZ group. Bacteria disappearance in patients evaluated seven days after completion of treatment was 100% (40/40 cases) in the TAZ/PIPC group and 95.7% (44/46 cases) in the CAZ group. Bacteria disappearance in pathogens was 100% (44/44 strains) in the TAZ/PIPC group and 95.8% (46/48 strains) in the CAZ group. 3. Safety: The incidence of test-drug-related adverse events was 49.3% (67/136 patients) in the TAZ/PIPC group and 37.0% (51/138 patients) in the CAZ group. The incidence of laboratory test abnormalities was 272% (37/136 patients) in the TAZ/PIPC group and 31.9% (44/138 patients) in the CAZ group. No statistically significant difference was seen between groups. These results indicate that a three-times-daily administration of 4.5 g TAZ/PIPC is expected to be highly effective in treating patients with community-acquired pneumonia.
AB - A randomized, unblinded, multicenter study was conducted to compare efficacy and safety of tazobactam/piperacillin(TAZ/PIPC), a β-lactamase inhibitor combined with penicillin antibiotic, to those of ceftazidime (CAZ) in patients with community-acquired pneumonia. Subjects were assigned to TAZ/PIPC (4.5 g three times daily) or CAZ (2 g twice daily) groups for a maximum administration of 14 days. Results were obtained as follows: 1. Clinical effect: Response at completion or discontinuation of treatment was 91.3% (95/104 patients) in the TAZ/PIPC group and 89.9% (98/109 patients) in the CAZ group. These results verified the noninferiority of TAZ/PIPC to CAZ in clinical effect. Response evaluated seven days after completion of treatment was 90.8% (89/98 patients) in the TAZ/PIPC group and 84.8% (89/105 patients) in the CAZ group. 2. Bacteriological effect: Bacteria disappearance in patients at completion or discontinuation of treatment was 100% (45/45 patients) in the TAZ/PIPC group and 93.8% (45/48 patients) in the CAZ group. Bacteria disappearance in pathogens was 100% (49/49 strains) in the TAZ/PIPC group and 94.0% (47/50 strains) in the CAZ group. Bacteria disappearance in patients evaluated seven days after completion of treatment was 100% (40/40 cases) in the TAZ/PIPC group and 95.7% (44/46 cases) in the CAZ group. Bacteria disappearance in pathogens was 100% (44/44 strains) in the TAZ/PIPC group and 95.8% (46/48 strains) in the CAZ group. 3. Safety: The incidence of test-drug-related adverse events was 49.3% (67/136 patients) in the TAZ/PIPC group and 37.0% (51/138 patients) in the CAZ group. The incidence of laboratory test abnormalities was 272% (37/136 patients) in the TAZ/PIPC group and 31.9% (44/138 patients) in the CAZ group. No statistically significant difference was seen between groups. These results indicate that a three-times-daily administration of 4.5 g TAZ/PIPC is expected to be highly effective in treating patients with community-acquired pneumonia.
KW - Ceftazidime
KW - Community-acquired pneumonia
KW - Randomized clinical trial
KW - Tazobactam/piperacillin
UR - http://www.scopus.com/inward/record.url?scp=77950788194&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950788194&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:77950788194
VL - 58
SP - 29
EP - 49
JO - Japanese Journal of Chemotherapy
JF - Japanese Journal of Chemotherapy
SN - 1340-7007
IS - SUPPL. 1
ER -